NCT01038778 2026-03-18
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT02453620 2026-03-18
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04708470 2025-12-31
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT02115282 2025-12-18
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03978624 2025-10-15
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03179930 2025-07-23
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03501381 2023-09-01
High Dose IL 2 and Entinostat in RCC
Hoosier Cancer Research Network
Phase 2 Active not recruiting